Form 4: CV insider Tsai Chen Lung receives 2,887 RSUs with year-end vesting

Rhea-AI Filing Summary

Tsai Chen Lung, a director of CapsoVision, Inc. (CV), reported receipt of 2,887 Restricted Stock Units (RSUs) on 09/15/2025. Each RSU represents a contingent right to one share of the company’s common stock and the reported RSUs carry a $0 price. The RSUs are scheduled to vest on December 31, 2025, and following the reported transaction the filing shows 2,887 shares beneficially owned directly. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/17/2025.

Positive

• Disclosure of insider award: Form 4 transparently reports the grant of 2,887 RSUs to a director
• Clear vesting schedule: RSUs are explicitly scheduled to vest on December 31, 2025

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine director equity award disclosed; vesting schedule and zero-dollar grant price are disclosed.

The filing documents a standard equity compensation event for a board member: 2,887 RSUs granted on 09/15/2025 with vesting on 12/31/2025 and a reported grant price of $0. As a governance matter, disclosure on Form 4 provides transparency about insider holdings and potential future share issuance on vesting. The direct ownership post-transaction is stated as 2,887 shares, which clarifies immediate beneficial ownership. There is no additional context in the filing about why the award was made or whether it is part of a recurring compensation program.

Securities Analyst

TL;DR: Non-derivative RSU award reported; filing is routine and carries limited immediate market impact.

The reported transaction is a non-derivative equity award representing contingent rights to common stock. Key explicit facts: grant date 09/15/2025, 2,887 RSUs, vesting 12/31/2025, and the filing shows 2,887 shares beneficially owned following the transaction. The Form 4 contains no pricing beyond a $0 entry for the RSUs and no details on broader dilution, plan terms, or prior holdings. Based solely on the disclosure, this appears to be a routine insider compensation event with no additional material information provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Tsai Chen Lung

(Last) (First) (Middle)

C/O CAPSOVISION, INC.

18805 COX AVENUE, SUITE 250

(Street)

SARATOGA CA 95070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CapsoVision, Inc [ CV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit (RSU)	(1)	09/15/2025		A		2,887		(2)	(2)	Common Stock	2,887	$0	2,887	D

Explanation of Responses:

1. Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.

2. These RSUs are scheduled to vest on December 31, 2025

Remarks:

	/s/ Kang-Huai (Johnny) Wang, Attorney-in-Fact for Chen Lung Tsai	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CapsoVision (CV) director Tsai Chen Lung receive on 09/15/2025?

The filing reports receipt of 2,887 Restricted Stock Units (RSUs) on 09/15/2025.

When do the RSUs granted to Tsai Chen Lung vest?

The RSUs are scheduled to vest on December 31, 2025.

How many shares does the Form 4 show as beneficially owned after the transaction?

The Form 4 shows 2,887 shares beneficially owned following the reported transaction.

What price was reported for the RSU grant in the Form 4?

The RSUs are reported with a $0 price in the filing.

Who signed the Form 4 filing for Tsai Chen Lung?

The Form 4 was signed by Kang-Huai (Johnny) Wang, Attorney-in-Fact, on 09/17/2025.